Overall response by UC
| . | UC . | |||
|---|---|---|---|---|
| All patients (N = 25), % (95% CI) . | Patients in expansion phase (at MTD) (N = 15), % (95% CI) . | |||
| Response | ||||
| sCR | n = 0 | 0 (0-22) | n = 0 | 0 (0-22) |
| CR | n = 2 | 8 (1-26) | n = 1 | 7 (0-32) |
| VGPR | n = 7 | 28 (12-49) | n = 4 | 27 (8-55) |
| PR | n = 6 | 24 (9-45) | n = 3 | 20 (4-48) |
| Stable disease | n = 5 | 20 (7-41) | n = 4 | 27 (8-55) |
| PD | n = 1 | 4 (0-20) | n = 1 | 7 (0-32) |
| Not evaluable* | n = 4 | 16 (5-36) | n = 2 | 13 (2-40) |
| Overall response (sCR + CR + VGPR + PR) | n = 15 | 60 (39-79) | n = 8 | 53 (27-79) |
| . | UC . | |||
|---|---|---|---|---|
| All patients (N = 25), % (95% CI) . | Patients in expansion phase (at MTD) (N = 15), % (95% CI) . | |||
| Response | ||||
| sCR | n = 0 | 0 (0-22) | n = 0 | 0 (0-22) |
| CR | n = 2 | 8 (1-26) | n = 1 | 7 (0-32) |
| VGPR | n = 7 | 28 (12-49) | n = 4 | 27 (8-55) |
| PR | n = 6 | 24 (9-45) | n = 3 | 20 (4-48) |
| Stable disease | n = 5 | 20 (7-41) | n = 4 | 27 (8-55) |
| PD | n = 1 | 4 (0-20) | n = 1 | 7 (0-32) |
| Not evaluable* | n = 4 | 16 (5-36) | n = 2 | 13 (2-40) |
| Overall response (sCR + CR + VGPR + PR) | n = 15 | 60 (39-79) | n = 8 | 53 (27-79) |
sCR indicates stringent CR; and PD, progressive disease.
Patients came off study prior to the first scheduled assessment prior to cycle 3.